Press releases
- Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
- Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Sage Therapeutics to Participate in Upcoming May Investor Conferences
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
More ▼
Key statistics
On Friday, SAGE Therapeutics Inc (SG7:MUN) closed at 9.91, 1.27% above its 52-week low of 9.78, set on Jun 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.91 |
---|---|
High | 9.91 |
Low | 9.91 |
Bid | 9.91 |
Offer | 9.96 |
Previous close | 9.93 |
Average volume | 0.00 |
---|---|
Shares outstanding | 60.18m |
Free float | 53.00m |
P/E (TTM) | -- |
Market cap | 648.76m USD |
EPS (TTM) | -8.40 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 07:08 BST.
More ▼